

# ASTRAZENECA PLC

ISIN: GB0009895292 WKN: 0989529 Asset Class: **Stock**

## Company

2024/07/05 17:35:01

Price

**12,056.00**

GBp

Difference

▼ -0.41% (-50.00)



## Contact Details

ASTRAZENECA PLC

Tel: +44-20-3749-5000

--

Fax: +

Cambridge Biomedical Campus,

Web:

1 Francis Crick Avenue

<http://www.astrazeneca.co.uk>

CB2 0AA Cambridge

E-mail: -

## Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	19,653,278,000		18,782,109,000		19,376,130,000	
<b>Common stock capital</b>		304,361,000		321,722,000		285,724,000
<b>Fixed assets</b>	59,668,183,000		61,426,552,000		58,414,116,000	
<b>Equity capital of a company</b>		30,723,250,000		30,807,215,000		29,005,869,000
<b>Cash and cash equivalents</b>	4,581,110,000		5,125,945,000		4,672,745,000	
<b>Accrued liabilities</b>		2,076,404,000		1,715,853,000		2,517,627,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		23,958,267,000		21,858,009,000		16,681,309,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		24,639,943,000		27,543,436,000		32,103,067,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		2,116,410,000		3,686,091,000		3,675,292,000
<b>Total assets</b>	79,321,462,000	79,321,462,000	80,208,662,000	80,208,662,000	77,790,246,000	77,790,246,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	89,900	83,500	83,100
<b>Equity ratio</b>	38.76%	38.43%	37.31%
<b>Debt-equity ratio</b>	158.03%	160.21%	168.06%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	13.57%	-31.60%	189.05%

# ASTRAZENECA PLC

ISIN: GB0009895292 WKN: 0989529 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	36,853,651,000	36,005,612,000	27,508,829,000
<b>Net income</b>	4,790,628,000	2,669,307,000	81,436,000
<b>EBIT</b>	7,367,522,810	3,181,333,701	481,904,704
<b>Operating income before taxes</b>	5,559,703,000	2,034,453,000	-146,149,000
<b>Cash Flow</b>	8,553,142,000	8,011,169,000	4,360,490,000
<b>Net interest income</b>	-676,560,000	-658,396,000	-554,059,000
<b>Research and development expenses</b>	8,322,259,000	7,825,259,000	6,214,626,000
<b>Income taxes</b>	754,594,000	-642,971,000	-276,302,000
<b>Result from investments in subsidiaries, associates and other</b>	-9,653,000	-4,059,000	-46,535,000
<b>Revenues per employee</b>	484,304	509,426	391,082

## Board of Directors

Michel Demaré	Chairman of Supervisory Board
Andreas Rummelt	Member of Supervisory Board
Aradhana Sarin	Member of Supervisory Board
Euan Ashley	Member of Supervisory Board
Nazneen Rahman	Member of Supervisory Board
Shu Kam Mok	Member of Supervisory Board
Anna Olive Magdelene Manz	Member of Supervisory Board
Deborah DiSanzo	Member of Supervisory Board
Diana Layfield	Member of Supervisory Board
Marcus Wallenberg	Member of Supervisory Board
Philip Broadley	Member of Supervisory Board
Sherilyn McCoy	Member of Supervisory Board

## Members of Management Board

Pascal Soriot	Chairman of Managing Board
Aradhana Sarin	Member of Executive Committee
Ruud Dobber	Member of Executive Committee
David Fredrickson	Member of Executive Committee
Iskra Reic	Member of Executive Committee
Jeff Pott	Member of Executive Committee
Leon Wang	Member of Executive Committee
Marc Dunoyer	Member of Executive Committee
Menelas (Mene) Pangalos	Member of Executive Committee
Pam Cheng	Member of Executive Committee
Sharon Barr	Member of Executive Committee
Susan Galbraith	Member of Executive Committee